BIIB Q4 2017 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.3B+15.1% YoY

Gross Profit

$2.8B84.6% margin

Operating Income

$1.5B44.3% margin

Net Income

-$297M-9.0% margin

EPS (Diluted)

$-1.41

QoQ Revenue Growth

+7.4%

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.2B

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$23.7B

Total Liabilities

$11.1B

Stockholders' Equity

$12.6B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.3B	$2.9B	+15.1%
Gross Profit	$2.8B	$2.5B	+9.9%
Operating Income	$1.5B	$886M	+65.4%
Net Income	-$297M	$649M	-145.8%